Article Text

Download PDFPDF

EPV172/#118 Olaparib single- centre experience in relapsed epithelial ovarian cancer in Slovenia
  1. B Gregorič and
  2. E Škof
  1. Institute of Oncology Ljubljana, Medical Oncology Department, Ljubljana, Slovenia


Objectives To evaluate the safety and efficacy of olaparib in treatment of patients with BRCA 1/2 mutated relapsed epithelial ovarian cancer.

Methods Retrospective analysis of patients with BRCA 1/2 mutated relapsed epithelial ovarian cancer treated with olaparib at the Institute of Oncology Ljubljana in the period from Nov 2015 to Dec 2020.

Results In the observed period, a total of 88 patients with BRCA 1/2 mutated relapsed epithelial ovarian cancer were treated with olaparib. Median age of patients was 60 years. Majority of patients (61%) had 1st relapse of the disease. Majority of patients (74%) had germline BRCA 1 gene mutation. Majority of patients (85%) had at least one adverse event during olaparib treatment. The most common adverse events (all grades) were: nausea (59%), fatigue (59%), anemia (25%), dispepsia (14%), diarrhea (11%), dysgeusia (10%), neutropenia (6%) and arrhythmia (1%). Severe adverse events (grade 3/4) had 10% of patients: anemia 9%, nausea 1%. Median follow up was 40 months. Median PFS was 14,3 months, median OS was 20,4 months. PFS was in correlation to the type of BRCA gene mutation: 80% of patients with somatic BRCA 1/2 gene mutation were progression-free, 55% of patients with germline BRCA 2 gene mutation were progression-free, while 32% of patients with germline BRCA 1 gene mutation were progression-free (p=0,021). The type fo BRCA 1/2 gene mutation did not correlate with OS.

Conclusions Analysis shows olaparib is safe and effective maintainance treatment in BRCA1/2 relapsed epithelial ovarian cancer with results that a comparable to those published in Study19 and SOLO-2.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.